News
EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 0.69 euros per share to the Annual Shareholders’ Meeting
EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech S.A. successfully completes a EUR 1.2 billion share capital increase without shareholders’ preferential subscription rights
Sartorius Stedim Biotech S.A. announces an offering of approximately 1.2 billion euros of new shares without shareholders’ preferential subscription rights by means of an accelerated bookbuilding
EQS-News: Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years.
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlook
Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
EQS-News: Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
EQS-News: Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
EQS-News: Abivax 2024 Financial Communication Calendar
Poxel Announces its Financial Calendar for 2024
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Poxel Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below.
Transgene will meet